MARKET

OGEN

OGEN

Oragenics
AMEX
0.9596
+0.0752
+8.50%
After Hours: 0.9592 -0.0004 -0.04% 19:01 03/12 EDT
OPEN
0.9890
PREV CLOSE
0.8844
HIGH
1.040
LOW
0.9302
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
0.6111
MARKET CAP
4.00M
P/E (TTM)
-0.0559
1D
5D
1M
3M
1Y
5Y
1D
Oragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up
NASDAQ · 8h ago
Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia
Benzinga · 10h ago
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions
TipRanks · 21h ago
Oragenics explores potential acquisition of additional assets in CNS space
TipRanks · 1d ago
Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed
Benzinga · 1d ago
Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
TipRanks · 2d ago
Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment
Benzinga · 2d ago
Weekly Report: what happened at OGEN last week (0302-0306)?
Weekly Report · 3d ago
More
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Webull offers Oragenics Inc stock information, including AMEX: OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.